Picture of Tempest Therapeutics logo

TPST — Tempest Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Tempest Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Tempest Therapeutics Inc  TPST.OQ  reported a quarterly
adjusted
loss of 42 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -54 cents.  The mean expectation of six analysts
for the quarter was for a loss of 40 cents per share. Wall
Street expected results to range from -56 cents to -33 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tempest Therapeutics Inc's reported EPS for the quarter
was a
loss of 42 cents​.
    * The company reported a quarterly loss of $9.57 million.
    * Tempest Therapeutics Inc shares had fallen by 36.1% this
quarter and lost 68.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 12.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $13.00 
This summary was machine generated from LSEG data August 8 at
10:56 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.40          -0.42          Missed
 Mar. 31 2024      -0.37          -0.36          Beat
 Dec. 31 2023      -0.39          -0.38          Beat
 Sep. 30 2023      -0.57          -0.48          Beat

Recent news on Tempest Therapeutics

See all news